Veeva Systems (VEEV) is back in focus after unveiling Falcon, an AI platform aimed at automating key drug development tasks, along with fresh global deals with Kindeva, Merck KGaA, and Teva for its cloud and CRM products.

Those customer wins and the Falcon launch sparked a sharp move, with a 7 day share price return of 15.39% helping to offset a year to date share price decline of 16.65%. The 1 year total shareholder return is down 35.75%, which suggests that recent momentum is building from a weak longer term base.

If Falcon and healthcare focused AI tools are on your radar, it could be worth scanning the wider opportunity set with Simply Wall St's screener for 39 healthcare AI stocks

With Veeva Systems trading at $182.94, an intrinsic value estimate that sits 38% higher and an analyst price target that is 44% above the current level raise a key question: is there a buying opportunity here, or is the market already pricing in future growth?

Most Popular Narrative: 30.4% Undervalued

Veeva Systems is priced at $182.94, while the most followed narrative suggests a fair value of about $262.68, using a 7.99% discount rate to get there.

The resolution of the long-standing dispute with IQVIA removes critical data interoperability barriers, enabling Veeva to fully integrate industry-leading datasets into its Commercial Cloud, which should materially expand its addressable market, improve product adoption across multiple commercial applications, and accelerate top-line revenue growth over the next several years.

Read the complete narrative. Read the complete narrative.

Curious how that fair value holds up? The narrative leans on steady double digit revenue growth, rising margins, and a richer earnings multiple to support that higher price.

Result: Fair Value of $262.68 (UNDERVALUED)

However, this hinges on broader adoption of Falcon and Vault CRM. Slower customer uptake or rising competition in healthcare focused AI and CRM could quickly weaken that case.

Another Angle On Valuation

The SWS DCF model points to a fair value of $295.07 for Veeva Systems, compared to the current price of $182.94, which implies the stock is trading below that cash flow based estimate. That sits alongside the analyst driven fair value of $262.68 and raises a simple question: which set of assumptions do you trust more?

Next Steps

With sentiment in this article leaning constructive, it makes sense to check the underlying data yourself and decide how compelling the setup looks. To see what the market currently views as the key bright spots, start with our breakdown of 3 key rewards

Looking for more investment ideas?

Do not stop with a single stock. Use this moment to line up a few fresh ideas so you are ready when the next setup appears.

• Hunt for potential bargains by scanning 47 high quality undervalued stocks that pair financial quality with prices below their estimated worth.
• Strengthen the defensive side of your portfolio by checking 63 resilient stocks with low risk scores that score well on resilience and downside protection.
• Get ahead of the crowd by reviewing a screener containing 22 high quality undiscovered gems before they appear on everyone else's radar.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.